613O - Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targ...

Date 09 October 2016
Event ESMO 2016 Congress
Session Gastrointestinal tumours, non-colorectal 2
Topics Gastrointestinal Cancers
Presenter Michael Overman
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors M.J. Overman1, A.B. Schrock2, C.E. Devoe3, R. McWilliams4, J. Sun5, J.T. Ruggiero6, P. Stephens7, J.S. Ross8, R. Wilson9, V.A. Miller10, S.M. Ali10
  • 1Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 3Northwell Health, The Monter Cancer Cencer, Lake Success/US
  • 4Medical Oncology, Mayo Clinic, Rochester/US
  • 5Biomarker Development, Foundation Medicine, Inc., Cambridge/US
  • 6Medical Oncology, Weill Cornell Medical College, New York/US
  • 7Clinical Genomics, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 8Pathology, Foundation Medicine, Inc., Cambridge/US
  • 9Centre For Cancer Research And Cell Biology, Queen's University Belfast, BT9 7JL - Belfast/GB
  • 10Clinical Development, Foundation Medicine, Inc., Cambridge/US



Small bowel adenocarcinomas (SBAs) are rare cancers with significantly lower incidence, later stage at diagnosis, and worse overall survival than other intestinal derived cancers including colorectal cancer (CRC). To date, comprehensive genomic characterization and identification of targetable genomic alterations in SBA is lacking.


We prospectively analyzed clinical samples from 358 patients with SBA, 6,353 patients with CRC, and 889 patients with gastric carcinoma (GC) using hybrid-capture based comprehensive genomic profiling (CGP).


We compared available clinical features and complete molecular profiles for SBA, CRC and GC patients. In all three series the majority were male (52-55%) and SBA patients tended to be marginally older (median 60 years old). APC alterations were less frequent in SBA (27%) than in CRC (76%) (P 


This study presents the first large scale genomic comparison of SBA with CRC and GC, as well as a comparison of unspecified SBAs with tumors of the duodenum. Higher incidence of microsattelite instability in SBA suggests that an important subset of these patients may benefit from treatment with anti-PD-1/PD-L1 therapies. The use of CGP during the course of clinical care identifies targetable genomic alterations across intestinal tumor types and allows patients to be matched with appropriate targeted therapies.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.


Foundation Medicine, Inc.


A.B. Schrock, J. Sun, P. Stephens, J.S. Ross, V.A. Miller, S.M. Ali: Employee at Foundation Medicine. Stock ownership: Foundation Medicine. All other authors have declared no conflicts of interest.